Sanara MedTech Inc.

deck on the Investor Relations page of our website. This supplemental deck, as well as a copy of the earnings release and the Form 10-Q for the quarter ended March 31, 2024, are also available on this page. We will reference this information in our remarks today. With us today are Ron Nixon, our Executive Chairman and CEO, Mike McNeil, our Chief Financial Officer, and Seth Yohn, our President Commercial. Please note that certain statements in this conference call, in our press release, and in our supplemental deck include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For more information about the risks and uncertainties involving forward-looking statements and factors that could cause actual results to differ materially from those projected or implied by forward-looking statements, please see the risk factors set forth in our most recent annual report on Form 10-K, as supplemented by the risk factors in our most recent quarterly report on Form 10-Q. Also, this conference call, our earnings release, and supplemental deck reference certain non-GAAP measures. In that regard, I direct you to the reconciliation of these measures and the earnings materials that are available on our website. Now I'd like to turn the call over to Ron.

Thank you, Callan, and good morning, everyone. As we mentioned in our press release yesterday, our former CEO, Zach Fleming, resigned on Friday. We're in the process of finalizing a separation agreement with Zach, and I've been appointed CEO by the company's board of directors. As a result of Zach's departure, the company will no longer be presenting the proposal for the election of a ninth director on our board of directors at the annual meeting of shareholders in June. As many of you know, I've been intimately involved with the leadership team in developing and executing Cenera's strategic vision since the inception of Cenera MedTech. And I'm looking forward to working with the Cenera's leadership team now on a daily basis to continue that execution. Turn into our first quarter results. First quarter of 2024 was the company's 10th consecutive record quarter. The company generated 18.5 million in revenue in Q1. Over the course of 2023, we made significant advancements in data analytics, Salesforce optimization, and sales processes. As I've told many of you before, when you're in a high growth business, you need to be able to build infrastructure, data analytics, and details around these processes in order to be able to improve to continue that growth. We believe that that's been implemented and that will pay dividends going forward. These improvements and the momentum we've achieved in the fourth quarter helped us to exceed our forecast for the first quarter. And we believe position us to continue to build upon the success the teams achieved in previous periods. But the three months ended March 31st, 2024, coming at a net loss of 1.8 million while we generated positive adjusted EBITDA of 300,000 over the same period. I'd like to provide a brief update on our partnership with InfuSystem. We continue to invest in this partnership and are focused on three potential areas of opportunity. The first initiative for the partnership is to distribute Cenera's advanced wound care products, including Bicos and Hycol, as well as negative pressure wound therapy products into long-term care, skilled nursing facilities, and wound centers. Building upon the strategic objectives, we're also exploring emerging opportunities for InterSystem to distribute our advanced wound care products outside of this channel. We also believe that our partnership will play a key role in Tissue Health Plus, our value-based care strategy that you've heard about many times before, which is planned to include standardized wound prevention and treatment plans that utilize Senera's wound care products. As these opportunities continue to develop, we will provide additional updates. And as I mentioned in our last call, we're having discussions with potential partners participating in the execution of the Tissue Health Plus strategy. During the process, we're continuing to invest in the technology, capabilities, and infrastructure that we believe are required to commercialize this very well-designed strategy. But we do not anticipate that this will continue spending by us alone in 2024, and we hope to have our partnerships in place so that we can execute. And these partners we're looking for are not just financial partners, they are strategic partners. We're also continuing focusing expansion of the existing surgical product offering. Lastly, we made significant progress in the area of intellectual property and manufacturing processes for Celerate product line itself. We think that this has been something we've talked about for many times, and we believe that it's got a significant ability for us to be able to get more IP around the product as we continue to advance this through many of the different specialties. I can now introduce you to Seth Yon, President of Commercial. Seth has been with the company since 2018, and over the years has been promoted multiple times to roles of increasing responsibility. In his current position as President of Commercial, he leads our national sales team and multiple internal teams, including marketing, customer support, national accounts, and business operations. He's been instrumental in building out our sales team and infrastructure scenario, and I look forward to working closely with him on the execution of our strategy.

Seth, I'll now turn it over to you to discuss our surgical sales results in more detail.